{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"The event-free survival distributions of patients with Stage II-IV diffuse anaplastic Wilms' tumor on AREN0321 and NWTS-5 (NCT00002610) were compared using the log-rank test.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"OTHER","pValue":".0199","paramType":"Log Rank Test Statistic","paramValue":"5.4190","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.5","upperLimit":"89.6","value":"76.1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"67.4","value":"25.0"},{"groupId":"OG002","lowerLimit":"64.6","upperLimit":"100.0","value":"87.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Compare the outcome of patients treated with alternating CyCE/VDCy chemotherapy (with or without vincristine/irinotecan cycles) to a fixed outcome based on that seen for similar patients treated with NWTS-5 (NCT00002610).","dispersionType":"95% Confidence Interval","groups":[{"description":"Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide; x 30 weeks; XRT.","id":"OG000","title":"UH-1"},{"description":"Window therapy of vincristine/irinotecan;Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide; x 30 weeks; XRT.","id":"OG001","title":"Window/UH-1"},{"description":"Window therapy of vincristine/irinotecan;Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide; x 36 weeks; XRT.","id":"OG002","title":"UH-2"}],"paramType":"NUMBER","populationDescription":"Eligible patients with Stage II-IV DAWT.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)","type":"PRIMARY","unitOfMeasure":"Percentage of 4-year OS"}